2010
Randomised clinical trial: a novel rabeprazole extended release 50 mg formulation vs. esomeprazole 40 mg in healing of moderate‐to‐severe erosive oesophagitis – the results of two double‐blind studies
Laine L, Katz PO, Johnson DA, Ibegbu I, Goldstein MJ, Chou C, Rossiter G, Lu Y. Randomised clinical trial: a novel rabeprazole extended release 50 mg formulation vs. esomeprazole 40 mg in healing of moderate‐to‐severe erosive oesophagitis – the results of two double‐blind studies. Alimentary Pharmacology & Therapeutics 2010, 33: 203-212. PMID: 21114792, DOI: 10.1111/j.1365-2036.2010.04516.x.Peer-Reviewed Original ResearchConceptsHeartburn resolutionErosive oesophagitisExtended releaseLA grade CSevere erosive oesophagitisDouble-blind trialDouble-blind studyPossibility of benefitCurrent PPIsD oesophagitisSevere oesophagitisGERD patientsSecondary endpointsPrimary endpointSymptomatic resolutionAcid suppressionSubgroup analysisDrug exposureClinical trialsOesophagitisGrade DGrade CFurther evaluationEsomeprazoleAcid inhibition
2009
Endoscopy of the esophagus in gastroesophageal reflux disease: are we losing sight of symptoms? Another perspective
Sharma P, Chey W, Hunt R, Laine L, Malfertheiner P, Wani S. Endoscopy of the esophagus in gastroesophageal reflux disease: are we losing sight of symptoms? Another perspective. Diseases Of The Esophagus 2009, 22: 461-466. PMID: 19191851, DOI: 10.1111/j.1442-2050.2008.00934.x.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsGastroesophageal reflux diseaseGERD-like symptomsSuppressive therapyReflux diseaseAcid suppressive therapyErosive reflux diseaseProspective multicenter studyCommon chronic disorderPrimary care physiciansPrimary care settingSymptom-based classificationSymptom-based diagnosisHuge economic burdenInternational Consensus GroupErosive esophagitisGERD patientsTroublesome symptomsEmpiric trialPartial responseComplete responseCare physiciansImpaired qualityMulticenter studyBarrett's esophagusChronic disorders